Sugi Predict

Sugi Predict / Compounds / SCHEMBL21998123

SCHEMBL21998123

SCHEMBL21998123

CN(CCCOCCO)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.38
▸ CA14 Q9ULX7 1/20 0.37
▸ L3MBTL1 Q9Y468 4/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ THRB P10828 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CHRNB2 P17787 1/20 0.34
▸ CHRNB4 P30926 1/20 0.34
▸ CHRNA3 P32297 1/20 0.34
▸ CHRNA4 P43681 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ CYP4F2 P78329 1/20 0.33
▸ CYP4A11 Q02928 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16205754 0.90 PDK2 (0.38) TSHRCA14L3MBTL1MEN1KMT2A
SCHEMBL30244640 0.88 MEN1 (0.38) TSHRCA14L3MBTL1MEN1KMT2A
SCHEMBL30379662 0.88 MEN1 (0.38) TSHRCA14L3MBTL1MEN1KMT2A
SCHEMBL25937523 0.88 MEN1 (0.38) TSHRCA14L3MBTL1MEN1KMT2A
SCHEMBL21107802 0.88 MEN1 (0.38) TSHRCA14L3MBTL1MEN1KMT2A
SCHEMBL850006 0.88 MEN1 (0.38) TSHRCA14L3MBTL1MEN1KMT2A
SCHEMBL21458670 0.88 MEN1 (0.38) TSHRCA14L3MBTL1MEN1KMT2A
SCHEMBL30380145 0.85 CA14 (0.36) CA14L3MBTL1MEN1KMT2ATHRB
SCHEMBL30380618 0.85 CA14 (0.36) CA14L3MBTL1MEN1KMT2ATHRB
SCHEMBL21996785 0.85 CA14 (0.36) CA14L3MBTL1HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-12337036-B2 Compounds and methods for trans-membrane delivery of molecules APOSENSE LTD (IL) 2025-06-24 — — US disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-20230089916-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-23 — — US disclosed
US-20220324854-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-13 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2020264490-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020264490-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TSHR 3319/4885CA14 4601/4885L3MBTL1 1394/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885CA14 4601/4885L3MBTL1 1394/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TSHR 3319/4885CA14 4601/4885L3MBTL1 1394/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TSHR 3319/4885CA14 4601/4885L3MBTL1 1394/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885CA14 4601/4885L3MBTL1 1394/4885
US-20220324854-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885CA14 4601/4885L3MBTL1 1394/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885CA14 4601/4885L3MBTL1 1394/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TSHR 3319/4885CA14 4601/4885L3MBTL1 1394/4885
US-20230089916-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK1, IRAK3 TSHR 2600/4885CA14 4794/4885L3MBTL1 120/4885
US-12337036-B2 Compounds and methods for trans-membrane delivery of molecules LDLR, NPC1L1, ABCB4 TSHR 2243/4885CA14 3526/4885L3MBTL1 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.